Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-02-2017 | Invited Review

Psychiatric disorders biochemical pathways unraveled by human brain proteomics

Authors: Verônica M. Saia-Cereda, Juliana S. Cassoli, Daniel Martins-de-Souza, Juliana M. Nascimento

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 1/2017

Abstract

Approximately 25 % of the world population is affected by a mental disorder at some point in their life. Yet, only in the mid-twentieth century a biological cause has been proposed for these diseases. Since then, several studies have been conducted toward a better comprehension of those disorders, and although a strong genetic influence was revealed, the role of these genes in disease mechanism is still unclear. This led most recent studies to focus on the molecular basis of mental disorders. One line of investigation that has risen in the post-genomic era is proteomics, due to its power of revealing proteins and biochemical pathways associated with biological systems. Therefore, this review compiled and analyzed data of differentially expressed proteins, which were found in postmortem brain studies of the three most prevalent psychiatric diseases: schizophrenia, bipolar disorder and major depressive disorders. Overviewing both the proteomic methods used in postmortem brain studies, the most consistent metabolic pathways found altered in these diseases. We have unraveled those disorders share about 21 % of proteins affected, and though most are related to energy metabolism pathways deregulation, the main differences found are 14-3-3-mediated signaling in schizophrenia, mitochondrial dysfunction in bipolar disorder and oxidative phosphorylation in depression.

Available only for authorised users

Chou I, Chouard T (2008) Neuropsychiatric disease. Nature 455:889. doi:10.1038/455889a PubMedCrossRef

Gillies D, Buykx P, Ag P, Se H (2015) Consultation liaison in primary care for people with mental disorders. Cochrane Libr. doi:10.1002/14651858.CD007193.pub2

World Health Organization N (2008) The global burden of disease: 2004 update. Update 2010:146. doi:10.1038/npp.2011.85

Van Heeringen C, Marušič A (2003) Understanding the suicidal brain. Br J Psychiatry 183:282–284. doi:10.1192/bjp.183.4.282 PubMedCrossRef

Nock MK, Hwang I, Sampson NA, Kessler RC (2010) Mental disorders, comorbidity and suicidal behavior: results from the National Comorbidity Survey Replication. Mol Psychiatry 15:868–876. doi:10.1038/mp.2009.29 PubMedCrossRef

Kessler R, Chiu W (2005) Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 62:617–627. doi:10.1001/archpsyc.62.6.617.Prevalence PubMedPubMedCentralCrossRef

Kessler RC, Petukhova M, Sampson NA et al (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 21:169–184. doi:10.1002/mpr.1359 PubMedPubMedCentralCrossRef

To S, Zepf R, Woods AG (2005) The symptoms, neurobiology, and current pharmacological treatment of depression. J Neurosci Nurs 32:102–107

American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5^®). doi:10.1176/appi.books.9780890425596.744053

10.

Rush A (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905. doi:10.1176/appi.ajp.163.11.1905 PubMedCrossRef

11.

Trivedi MH, Rush AJ, Wisniewski SR et al (2006) Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR* D report. J Clin Psychiatry 67:185–195PubMedCrossRef

12.

Kupfer DJ, Frank E, Phillips ML (2012) Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 379:1045–1055. doi:10.1016/S0140-6736(11)60602-8.Major PubMedCrossRef

13.

Belmaker RH, Agam G (2008) Major depressive disorder. N Engl J Med 358:55–68. doi:10.1056/NEJMra073096 PubMedCrossRef

14.

Krishnan V, Nestler EJ (2009) The molecular neurobiology of depression. Nature 455:894–902. doi:10.1038/nature07455.The CrossRef

15.

Freedman R (2003) Schizophrenia. N Engl J Med 349:1738–1749. doi:10.3760/cma.j.issn.0366-6999.20122551 PubMedCrossRef

16.

Sullivan PF, Kendler KS, Neale MC (2003) Schizophrenia as a complex trait. Arch Gen Psychiatry 60:1187–1192. doi:10.1001/archpsyc.60.12.1187 PubMedCrossRef

17.

Hegarty JD, Baldessarini RJ, Oepen G (1994) One hundred years of schizophrenia. Am J Psychiatry 151:1409–1416PubMedCrossRef

18.

Weickert TW, Goldberg TE, Gold JM et al (2000) Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 57:907–913. doi:10.1001/archpsyc.57.9.907 PubMedCrossRef

19.

Rapoport J (2012) Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry 17:1228–1238. doi:10.1038/mp.2012.23.Neurodevelopmental PubMedPubMedCentralCrossRef

20.

Keller T (2010) Diagnostic features, prevalence, and impact of bipolar disorder. J Clin Psychiatry. doi:10.4088/JCP.8125tx11c PubMedPubMedCentral

21.

Sussulini A (2014) Proteomics and metabolomics of bipolar disorder. Proteom Metabol Psychiatry 29:116. doi:10.1159/000358037

22.

Marmol F (2008) Lithium: bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium. Prog Neuropsychopharmacol Biol Psychiatry 32:1761–1771. doi:10.1016/j.pnpbp.2008.08.012 PubMedCrossRef

23.

Maj M (2003) The effect of lithium in bipolar disorder: a review of recent research evidence. Bipolar Disord 5:180–188PubMedCrossRef

24.

Fornito A, Harrison BJ (2012) Brain connectivity and mental illness. Front Psychiatry 3:1–2. doi:10.3389/fpsyt.2012.00072

25.

O’Farrell PH (1975) High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250:4007–4021. doi:10.1016/j.bbi.2008.05.010 PubMedPubMedCentral

26.

Oliveira BM, Coorssen JR, Martins-de-Souza D (2014) 2DE: the phoenix of proteomics. J Proteom 104:140–150. doi:10.1016/j.jprot.2014.03.035 CrossRef

27.

Unlü M, Morgan ME, Minden JS (1997) Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18:2071–2077. doi:10.1002/elps.1150181133 PubMedCrossRef

28.

Cramer R (2009) Difference gel electrophoresis (DIGE). Methods Mol Biol. doi:10.1007/978-1-62703-239-1_1

29.

Klose J, Kobalz U (1995) Two-dimensional electrophoresis of proteins: an updated protocol and implications for a functional analysis of the genome. Electrophoresis 16:1034–1059PubMedCrossRef

30.

Link AJ, Eng J, Schieltz DM et al (1999) Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 17:676–682. doi:10.1038/10890 PubMedCrossRef

31.

Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422:198–207. doi:10.1038/nature01511 PubMedCrossRef

32.

Kislinger T, Emili A (2003) Going global: protein expression profiling using shotgun mass spectrometry. Curr Opin Mol Ther 5:285–293PubMed

33.

Wolters DA, Washburn MP, Yates JR (2001) An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem 73:5683–5690. doi:10.1021/ac010617e PubMedCrossRef

34.

Taylor P, Nielsen PA, Trelle MB et al (2009) Automated 2D peptide separation on a 1D nano-LC-MS system. J Proteome Res 8:1610–1616. doi:10.1021/pr800986c PubMedCrossRef

35.

Rinas A, Jones LM (2014) Fast photochemical oxidation of proteins coupled to multidimensional protein identification technology (MudPIT): expanding footprinting strategies to complex systems. J Am Soc Mass Spectrom 26:540–546. doi:10.1007/s13361-014-1017-6 PubMedCrossRef

36.

MacLean B, Tomazela DM, Shulman N et al (2010) Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26:966–968. doi:10.1093/bioinformatics/btq054 PubMedPubMedCentralCrossRef

37.

Pernikářová V, Bouchal P (2015) Targeted proteomics of solid cancers: from quantification of known biomarkers towards reading the digital proteome maps. Expert Rev Proteomics 9450:1–17. doi:10.1586/14789450.2015.1094381

38.

Gygi SP, Rist B, Gerber SA et al (1999) Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17:994–999. doi:10.1038/13690 PubMedCrossRef

39.

Schmidt A, Kellermann J, Lottspeich F (2005) A novel strategy for quantitative proteomics using isotope-coded protein labels. Proteomics 5:4–15. doi:10.1002/pmic.200400873 PubMedCrossRef

40.

Ross PL (2004) Multiplexed protein quantitation in saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3:1154–1169. doi:10.1074/mcp.M400129-MCP200 PubMedCrossRef

41.

Gafken PR, Lampe PD (2006) Methodologies for characterizing phosphoproteins by mass spectrometry. Cell Commun Adhes 13:249–262. doi:10.1080/15419060601077917 PubMedPubMedCentralCrossRef

42.

Ong S, Mann M (2007) PROTOCOL A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc. doi:10.1038/nprot.2006.427

43.

Latosinska A, Vougas K, Makridakis M et al (2015) Comparative analysis of label-free and 8-plex iTRAQ approach for quantitative tissue proteomic analysis. PLoS ONE 10:e0137048. doi:10.1371/journal.pone.0137048 PubMedPubMedCentralCrossRef

44.

Wong JWH, Cagney G (2010) An overview of label-free quantitation methods in proteomics by mass spectrometry. Proteome Bioinforma 604:273–283. doi:10.1007/978-1-60761-444-9 CrossRef

45.

Lu P, Vogel C, Wang R et al (2007) Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nat Biotechnol 25:117–124. doi:10.1038/nbt1270 PubMedCrossRef

46.

Mallick P, Schirle M, Chen SS et al (2007) Computational prediction of proteotypic peptides for quantitative proteomics. Nat Biotechnol 25:125–131. doi:10.1038/nbt1275 PubMedCrossRef

47.

Ishihama Y (2005) Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 4:1265–1272. doi:10.1074/mcp.M500061-MCP200 PubMedCrossRef

48.

Silva JC (2005) Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics 5:144–156. doi:10.1074/mcp.M500230-MCP200 PubMedCrossRef

49.

Chelius D, Bondarenko P (2002) Quantitative profiling of proteins in complex mixtures using liquid chromatography and mass spectrometry. J Proteome Res 1:317–323PubMedCrossRef

50.

Martins-de-Souza D, Guest PC, Vanattou-Saifoudine N et al (2011) Proteomic technologies for biomarker studies in psychiatry: advances and needs. Int Rev Neurobiol. doi:10.1016/B978-0-12-387718-5.00004-3

51.

Picotti P, Aebersold R (2012) Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 9:555–566. doi:10.1038/nmeth.2015 PubMedCrossRef

52.

Lange V, Picotti P, Domon B, Aebersold R (2008) Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 4:222. doi:10.1038/msb.2008.61 PubMedPubMedCentralCrossRef

53.

Burgess MW, Keshishian H, Mani DR et al (2014) Simplified and efficient quantification of low-abundance proteins at very high multiplex via targeted mass spectrometry. Mol Cell Proteomics 13:1137–1149. doi:10.1074/mcp.M113.034660 PubMedPubMedCentralCrossRef

54.

Keshishian H, Addona T, Burgess M et al (2007) Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 6:2212–2229. doi:10.1074/mcp.M700354-MCP200 PubMedPubMedCentralCrossRef

55.

Anderson L, Hunter CL (2006) Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 5:573–588. doi:10.1074/mcp.M500331-MCP200 PubMedCrossRef

56.

Peterson AC (2012) Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell Proteomics 11(11):1475–1488. doi:10.1074/mcp.O112.020131 PubMedPubMedCentralCrossRef

57.

Tong L, Zhou XY, Jylha A et al (2015) Quantitation of 47 human tear proteins using high resolution multiple reaction monitoring (HR-MRM) based-mass spectrometry. J Proteom 115:36–48. doi:10.1016/j.jprot.2014.12.002 CrossRef

58.

Domon B, Gallien S (2015) Recent advances in targeted proteomics for clinical applications. PROTEOMICS Clin Appl. doi:10.1002/prca.201400136

59.

Schilling B, MacLean B, Held JM et al (2015) Multiplexed, scheduled, high-resolution parallel reaction monitoring on a full scan QqTOF instrument with integrated data-dependent and targeted mass spectrometric workflows. Anal Chem 87:10222–10229. doi:10.1021/acs.analchem.5b02983 PubMedCrossRef

60.

Ellington AA, Kullo IJ, Bailey KR, Klee GG (2010) Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem 56:186–193. doi:10.1373/clinchem.2009.127514.Antibody-Based PubMedCrossRef

61.

Kurien BT, Scofield RH (2015) Western blotting methods and protocols. doi:10.1007/978-1-4939-2694-7

62.

Lisitsyn NA, Chernyi AA, Nikitina IG et al (2014) Methods of protein immunoanalysis. Mol Biol 48:624–633. doi:10.1134/S0026893314050094 CrossRef

63.

Lynch HE, Sancheza AM, D’Souza MP (2015) Development and implementation of a proficiency testing program for Luminex bead-based cytokine assays. J Immunol Methods. doi:10.1016/j.jim.2014.04.011.Development

64.

Khan SS, Smith MS, Reda D et al (2004) Multiplex bead array assays for detection of soluble cytokines : comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom 39:35–39. doi:10.1002/cyto.b.20021 CrossRef

65.

Djoba Siawaya JF, Siawaya D, Roberts T et al (2008) An evaluation of commercial fluorescent bead-based luminex cytokine assays. PLoS ONE 3:1–12. doi:10.1371/journal.pone.0002535 CrossRef

66.

Nechansky A, Grunt S, Roitt IM, Kircheis R (2008) Comparison of the calibration standards of three commercially available multiplex kits for human cytokine measurement to WHO standards reveals striking differences. Biomark Insights 43:227–235

67.

Butterfield LH, Potter DM, Kirkwood JM (2011) Multiplex serum biomarker assessments : technical and biostatistical issues. J Transl Med 9:173. doi:10.1186/1479-5876-9-173 PubMedPubMedCentralCrossRef

68.

Scott ME, Wilson SS, Cosentino LA (2012) Interlaboratory reproducibility of female genital tract cytokine measurements by luminex: implications for microbicide safety studies. Cytokine 56:430–434. doi:10.1016/j.cyto.2011.06.011.Interlaboratory CrossRef

69.

Beasley CL, Pennington K, Behan A et al (2006) Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 6:3414–3425. doi:10.1002/pmic.200500069 PubMedCrossRef

70.

English JA, Dicker P, Föcking M et al (2009) 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 9:3368–3382. doi:10.1002/pmic.200900015 PubMedCrossRef

71.

Sivagnanasundaram S, Crossett B, Dedova I et al (2007) Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study. Proteomics Clin Appl 1:1291–1305. doi:10.1002/prca.200700230 PubMedCrossRef

72.

Martins-De-Souza D, Gattaz WF, Schmitt A et al (2009) Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci 259:151–163. doi:10.1007/s00406-008-0847-2 PubMedCrossRef

73.

Saia-Cereda VM, Cassoli JS, Schmitt A et al (2015) Proteomics of the corpus callosum unravel pivotal players in the dysfunction of cell signaling, structure, and myelination in schizophrenia brains. Eur Arch Psychiatry Clin Neurosci 265:601–612. doi:10.1007/s00406-015-0621-1 PubMedCrossRef

74.

Martins-De-Souza D, Gattaz WF, Schmitt A et al (2009) Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm 116:275–289. doi:10.1007/s00702-008-0156-y PubMedCrossRef

75.

Martins-de-Souza D, Gattaz WF, Schmitt A et al (2009) Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res 43:978–986. doi:10.1016/j.jpsychires.2008.11.006 PubMedCrossRef

76.

Martins-de-Souza D, Schmitt A, Röder R et al (2010) Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia. J Psychiatr Res 44:989–991. doi:10.1016/j.jpsychires.2010.03.003 PubMedCrossRef

77.

Martins-de-Souza D, Maccarrone G, Wobrock T et al (2010) Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res 44:1176–1189. doi:10.1016/j.jpsychires.2010.04.014 PubMedCrossRef

78.

Föcking M, Lopez LM, English JA et al (2014) Proteomic and genomic evidence implicates the postsynaptic density in schizophrenia. Mol Psychiatry. doi:10.1038/mp.2014.63 PubMed

79.

Johnston-Wilson NL, Sims CD, Hofmann JP et al (2000) Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry 5:142–149. doi:10.1038/sj.mp.4000696 PubMedCrossRef

80.

Prabakaran S, Swatton JE, Ryan MM et al (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9(684–697):643. doi:10.1038/sj.mp.4001532 CrossRef

81.

Clark D, Dedova I, Cordwell S, Matsumoto I (2006) A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry 11(459–470):423. doi:10.1038/sj.mp.4001806 CrossRef

82.

Pennington K, Beasley CL, Dicker P et al (2008) Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 13:1102–1117. doi:10.1038/sj.mp.4002098 PubMedCrossRef

83.

Martins-de-Souza D, Gattaz WF, Schmitt A et al (2009) Proteome analysis of schizophrenia patients Wernicke’s area reveals an energy metabolism dysregulation. BMC Psychiatry 9:17. doi:10.1186/1471-244X-9-17 PubMedPubMedCentralCrossRef

84.

Wesseling H, Gottschalk MG, Bahn S (2014) Targeted multiplexed selected reaction monitoring analysis evaluates protein expression changes of molecular risk factors for major psychiatric disorders. Int J Neuropsychopharmacol 18:pyu015. doi:10.1093/ijnp/pyu015 PubMedPubMedCentralCrossRef

85.

Föcking M, Dicker P, English JA et al (2011) Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. Arch Gen Psychiatry 68:477–488. doi:10.1001/archgenpsychiatry.2011.43 PubMedCrossRef

86.

Gottschalk MG, Wesseling H, Guest PC, Bahn S (2015) Proteomic enrichment analysis of psychotic and affective disorders reveals common signatures in presynaptic glutamatergic signaling and energy. Metabolism. doi:10.1093/ijnp/pyu019

87.

Martins-de-Souza D, Guest PC, Harris LW et al (2012) Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl Psychiatry 2:e87. doi:10.1038/tp.2012.13 PubMedPubMedCentralCrossRef

88.

Stelzhammer V, Alsaif M, Chan MK et al (2015) Distinct proteomic profiles in post-mortem pituitary glands from bipolar disorder and major depressive disorder patients. J Psychiatr Res 60:40–48. doi:10.1016/j.jpsychires.2014.09.022 PubMedCrossRef

89.

Calvano SE, Xiao W, Richards DR et al (2005) A network-based analysis of systemic inflammation in humans. Nature 437:1032–1037. doi:10.1038/nature04362 PubMedCrossRef

90.

Möller HJ (2003) Bipolar disorder and schizophrenia: distinct illnesses or a continuum? J Clin Psychiatry 64:23–27PubMed

91.

Craddock N (2005) Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull 32:9–16. doi:10.1093/schbul/sbj033 PubMedPubMedCentralCrossRef

92.

Berrettini WH (2000) Are schizophrenic and bipolar disorders related ? A review of family and molecular studies. Biolo Psychiatry 48(6):531–538. doi:10.1016/S0006-3223(00)00883-0 PubMedCrossRef

93.

Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Haroutunian V (2003) White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60(5):443–456PubMedCrossRef

94.

Du F, Cooper AJ, Thida T et al (2013) Myelin and axon abnormalities in schizophrenia. Biol Psychiatry 74:451–457. doi:10.1016/j.biopsych.2013.03.003 PubMedPubMedCentralCrossRef

95.

Flynn SW, Lang DJ, MacKay AL et al (2003) Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry 8:811–820. doi:10.1038/sj.mp.4001337 PubMedCrossRef

96.

Cassoli JS, Guest PC, Malchow B et al (2015) Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules. NPJ Schizophr 1:15034. doi:10.1038/npjschz.2015.34 PubMedPubMedCentralCrossRef

97.

Deloulme JC, Raponi E, Gentil BJ et al (2004) Nuclear expression of S100B in oligodendrocyte progenitor cells correlates with differentiation toward the oligodendroglial lineage and modulates oligodendrocytes maturation. Mol Cell Neurosci 27:453–465. doi:10.1016/j.mcn.2004.07.008 PubMedCrossRef

98.

Steiner J, Schmitt A, Schroeter ML et al (2014) S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum. Eur Arch Psychiatry Clin Neurosci 264:311–316. doi:10.1007/s00406-014-0490-z PubMedCrossRef

99.

Taveggia C (2016) Schwann cells–axon interaction in myelination. Curr Opin Neurobiol 39:24–29. doi:10.1016/j.conb.2016.03.006 PubMedCrossRef

100.

Fields RD (2008) White matter in learning, cognition and psychiatric disorders. Trends Neurosci 31:361–370. doi:10.1038/nature13314.A PubMedPubMedCentralCrossRef

101.

Tkachev D, Mimmack ML, Ryan MM et al (2003) Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362:798–805PubMedCrossRef

102.

Georgieva L, Moskvina V, Peirce T et al (2006) Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. Proc Natl Acad Sci USA 103:12469–12474. doi:10.1073/pnas.0603029103 PubMedPubMedCentralCrossRef

103.

Aston C, Jiang L, Sokolov BP (2005) Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry 10:309–322. doi:10.1038/sj.mp.4001565 PubMedCrossRef

104.

Aparicio S, Eaves C (2009) p53: a new kingpin in the stem cell arena. Cell 138:1060–1062PubMedCrossRef

105.

Liu H, Jia D, Li A et al (2013) p53 regulates neural stem cell proliferation and differentiation via BMP-Smad1 signaling and Id1. Stem Cells Dev 22:913–927. doi:10.1089/scd.2012.0370 PubMedCrossRef

106.

Eisch AJ, Cameron HA, Encinas JM et al (2009) Adult neurogenesis, mental health, and mental illness: hope or hype? J Neurosci 28:11785–11791. doi:10.1523/JNEUROSCI.3798-08.2008.Adult CrossRef

107.

Baldelli P, Meldolesi J (2015) The transcription repressor REST in adult neurons: physiology, pathology, and diseases (1, 2, 3). eNeuro. doi:10.1523/ENEURO.0010-15.2015 PubMedPubMedCentral

108.

Wang Q, Wang Y, Ji W et al (2015) SNAP25 is associated with schizophrenia and major depressive disorder in the Han Chinese population. J Clin Psychiatry 76:76–82. doi:10.4088/JCP.13m08962 CrossRef

109.

Biewenga JE, Schrama LH, Gispen WH (1996) Presynaptic phosphoprotein B-50/GAP-43 in neuronal and synaptic plasticity. Acta Biochim Pol 43:327–338PubMed

110.

Suzuki T, Mitake S, Okumura-Noji K et al (1997) Excitable membranes and synaptic transmission: postsynaptic mechanisms. Localization of alpha-internexin in the postsynaptic density of the rat brain. Brain Res 765:74–80PubMedCrossRef

111.

O’Dushlaine C, Rossin L, Lee PH et al (2015) Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci 18:199–209. doi:10.1038/nn.3922 CrossRef

112.

Lee SH (2013) Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. doi:10.1038/ng.2711

113.

Foote M, Zhou Y (2012) 14-3-3 proteins in neurological disorders. Int J Biochem Mol Biol 3:152–164PubMedPubMedCentral

114.

Tzivion G, Avruch J (2002) 14-3-3 proteins: active cofactors in cellular regulation by serine/threonine phosphorylation. J Biol Chem 277:3061–3064. doi:10.1074/jbc.R100059200 PubMedCrossRef

115.

Berg D, Holzmann C, Riess O (2003) 14-3-3 proteins in the nervous system. Nat Rev Neurosci 4:752–762. doi:10.1038/nrn1197 PubMedCrossRef

116.

Steinacker P, Aitken A, Otto M (2011) 14-3-3 proteins in neurodegeneration. Semin Cell Dev Biol 22:696–704. doi:10.1016/j.semcdb.2011.08.005 PubMedCrossRef

117.

Bell R, Munro J, Russ C et al (2000) Systematic screening of the 14-3-3 eta (eta) chain gene for polymorphic variants and case-control analysis in schizophrenia. Am J Med Genet 96:736–743PubMedCrossRef

118.

Foote M, Qiao H, Graham K et al (2015) Inhibition of 14-3-3 proteins leads to schizophrenia-related behavioral phenotypes and synaptic defects in mice. Biol Psychiatry 78:386–395. doi:10.1016/j.biopsych.2015.02.015 PubMedPubMedCentralCrossRef

119.

Schubert KO, Föcking M, Cotter DR (2015) Proteomic pathway analysis of the hippocampus in schizophrenia and bipolar affective disorder implicates 14-3-3 signaling, aryl hydrocarbon receptor signaling, and glucose metabolism: potential roles in GABAergic interneuron pathology. Schizophr Res. doi:10.1016/j.schres.2015.02.002 PubMed

120.

Wong AHC, Likhodi O, Trakalo J et al (2005) Genetic and post-mortem mRNA analysis of the 14-3-3 genes that encode phosphoserine/threonine-binding regulatory proteins in schizophrenia and bipolar disorder. Schizophr Res 78:137–146. doi:10.1016/j.schres.2005.06.009 PubMedCrossRef

121.

Cheah P-S, Ramshaw HS, Thomas PQ et al (2012) Neurodevelopmental and neuropsychiatric behaviour defects arise from 14-3-3ζ deficiency. Mol Psychiatry 17:451–466. doi:10.1038/mp.2011.158 PubMedCrossRef

122.

Qiao H, Foote M, Graham K et al (2014) 14-3-3 proteins are required for hippocampal long-term potentiation and associative learning and memory. J Neurosci 34:4801–4808. doi:10.1523/JNEUROSCI.4393-13.2014 PubMedPubMedCentralCrossRef

123.

Ruce MIC, Asile IONV, Asile MAV, Îlcea ALMAV (2015) c-abl and YWHAZ gene expression in gastric cancer. Rom J Morphol Embryol 56:717–723

124.

Toyo-oka K, Wachi T, Hunt RF et al (2014) 14-3-3Ε and Ζ regulate neurogenesis and differentiation of neuronal progenitor cells in the developing brain. J Neurosci 34:12168–12181. doi:10.1523/JNEUROSCI.2513-13.2014 PubMedPubMedCentralCrossRef

125.

Deka H, Sarmah R, Sharma A, Biswas S (2015) Modelling and characterization of glial fibrillary acidic protein. Bioinformation 11:393PubMedPubMedCentralCrossRef

126.

Webster MJ, O’Grady J, Kleinman JE, Weickert CS (2005) Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 133:453–461. doi:10.1016/j.neuroscience.2005.02.037 PubMedCrossRef

127.

Coyle JT, Schwarcz R (2013) Mind glue. Arch Gen Psychiatry 57:90–93CrossRef

128.

Magistretti PJ, Pellerin L (1999) Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci 354:1155–1163. doi:10.1098/rstb.1999.0471 PubMedPubMedCentralCrossRef

129.

Araque A, Sanzgiri RP, Parpura V, Haydon PG (1999) Astrocyte-induced modulation of synaptic transmission. Can J Physiol Pharmacol 77:7. doi:10.1139/cjpp-77-9-699 CrossRef

130.

Middeldorp J, Hol EM (2011) GFAP in health and disease. Prog Neurobiol 93:421–443. doi:10.1016/j.pneurobio.2011.01.005 PubMedCrossRef

131.

Pieczenik SR, Neustadt J (2007) Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 83:84–92. doi:10.1016/j.yexmp.2006.09.008 PubMedCrossRef

132.

Akarsu S, Torun D, Erdem M et al (2015) Mitochondrial complex I and III mRNA levels in bipolar disorder. J Affect Disord 184:160–163. doi:10.1016/j.jad.2015.05.060 PubMedCrossRef

133.

Kim D (2015) Methods of integrating data to uncover genotype–phenotype interactions. Nat Publ Gr. doi:10.1038/nrg3868

134.

Konradi C, Eaton M, MacDonald ML et al (2004) Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 61:300–308. doi:10.1001/archpsyc.61.3.300 PubMedCrossRef

135.

Quiroz JA, Gray NA, Kato T, Manji HK (2008) Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33:2551–2565. doi:10.1038/sj.npp.1301671 PubMedCrossRef

136.

Rollins B, Martin MV, Sequeira PA et al (2009) Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. PLoS ONE 4:e4913. doi:10.1371/journal.pone.0004913 PubMedPubMedCentralCrossRef

137.

Ohgi Y, Futamura T, Hashimoto K (2015) Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders. Curr Mol Med 15:206–221. doi:10.2174/1566524015666150330143008#sthash.K0d80Sgj.dpuf PubMedCrossRef

138.

Du J, Machado-Vieira R, Khairova R (2011) Synaptic plasticity in the pathophysiology and treatment of bipolar disorder. Curr Top Behav Neurosci. doi:10.1007/7854 PubMed

139.

Che M, Wang R, Wang H, Zheng XFS (2015) Expanding roles of superoxide dismutases in cell regulation and cancer. Drug Discov Today 21:1–7

140.

Tsang CK, Liu Y, Thomas J et al (2014) Superoxide dismutase 1 acts as a nuclear transcription factor to regulate oxidative stress resistance. Nat Commun 5:1–11. doi:10.1038/ncomms4446 CrossRef

141.

Coughlin JM, Ishizuka K, Kano SI et al (2013) Marked reduction of soluble superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with recent-onset schizophrenia. Mol Psychiatry 18:10–11. doi:10.1038/mp.2012.6 PubMedCrossRef

142.

Gigante AD, Andreazza AC, Lafer B et al (2011) Decreased mRNA expression of uncoupling protein 2, a mitochondrial proton transporter, in post-mortem prefrontal cortex from patients with bipolar disorder and schizophrenia. Neurosci Lett 505:47–51. doi:10.1016/j.neulet.2011.09.064 PubMedCrossRef

143.

Reddy R, Sahebarao MP, Mukherjee S, Murthy JN (1991) Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry 30:409–412. doi:10.1016/0006-3223(91)90298-Z PubMedCrossRef

144.

Tsai M-C, Huang T-L (2015) Thiobarbituric acid reactive substances (TBARS) is a state biomarker of oxidative stress in bipolar patients in a manic phase. J Affect Disord 173:22–26. doi:10.1016/j.jad.2014.10.045 PubMedCrossRef

145.

Tunçel ÖK, Sarısoy G, Bilgici B et al (2015) Oxidative stress in bipolar and schizophrenia patients. Psychiatry Res 228:688–694. doi:10.1016/j.psychres.2015.04.046 PubMedCrossRef

146.

Yao JK, Reddy RD, van Kammen DP (2001) Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15:287–310. doi:10.2165/00023210-200115040-00004 PubMedCrossRef

147.

Rubin CI, Atweh GF (2004) The role of stathmin in the regulation of the cell cycle. J Cell Biochem 93:242–250. doi:10.1002/jcb.20187 PubMedCrossRef

148.

Chauvin S, Sobel A (2014) Neuronal stathmins: A family of phosphoproteins cooperating for neuronal development, plasticity and regeneration. Prog Neurobiol 126:1–18. doi:10.1016/j.pneurobio.2014.09.002 PubMedCrossRef

149.

Smeitink J, van den Heuvel L, DiMauro S (2001) The genetics and pathology of oxidative phosphorylation. Nat Rev Genet 2:342–352. doi:10.1038/35072063 PubMedCrossRef

150.

Moslemi A-R, Darin N (2007) Molecular genetic and clinical aspects of mitochondrial disorders in childhood. Mitochondrion 7:241–252. doi:10.1016/j.mito.2007.02.002 PubMedCrossRef

151.

Martins-de-Souza D (2014) Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder. Dialogues Clin Neurosci 16:63–73PubMedPubMedCentral

152.

Rice MW, Smith KL, Roberts RC et al (2014) Assessment of cytochrome C oxidase dysfunction in the substantia nigra/ventral tegmental area in schizophrenia. PLoS ONE 9:e100054. doi:10.1371/journal.pone.0100054 PubMedPubMedCentralCrossRef

153.

Sawai H, Takai-igarashi T, Tanaka H (2015) Identification of collaborative activities with oxidative phosphorylation in bipolar disorder. Bioinformation 11:207PubMedPubMedCentralCrossRef

154.

Wesseling H, Chan MK, Tsang TM et al (2013) A combined metabonomic and proteomic approach identifies frontal cortex changes in a chronic phencyclidine rat model in relation to human schizophrenia brain pathology. Neuropsychopharmacology 38:2532–2544. doi:10.1038/npp.2013.160 PubMedPubMedCentralCrossRef

155.

Zubenko GS, Hughes HB, Jordan RM et al (2014) Differential hippocampal gene expression and pathway analysis in an etiology-based mouse model of major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 165B:457–466. doi:10.1002/ajmg.b.32257 PubMedCrossRef

156.

Conde C, Cáceres A (2009) Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci 10:319–332. doi:10.1038/nrn2631 PubMedCrossRef

157.

Inagaki N, Chihara K, Arimura N et al (2001) CRMP-2 induces axons in cultured hippocampal neurons. Nat Neurosci 4:781–782. doi:10.1038/90476 PubMedCrossRef

158.

Martins-de-souza D, Cassoli JS, Nascimento JM (2015) The protein interactome of collapsing response mediator protein-2 (CRMP2/DPYSL2) reveals novel partner proteins in brain tissue. Clin Relevance 2:1–25. doi:10.1002/prca.201500004.This

159.

Koide T, Aleksic B, Ito Y et al (2010) SHORT COMMUNICATION A two-stage case–control association study of with schizophrenia in Japanese subjects. J Hum Genet 55:469–472. doi:10.1038/jhg.2010.38 PubMedCrossRef

160.

Kessler RC, Aguilar-Gaxiola S, Alonso J et al (2011) The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc 18:23–33. doi:10.1017/S1121189X00001421 CrossRef

161.

Kessler RC, Berglund PA, Foster CL et al (1997) Social consequences of psychiatric disorders. 2. Teenage parenthood. Am J Psychiatry 154:1405–1411. doi:10.1176/ajp.154.10.1405 PubMedCrossRef

162.

Kessler RC, Walters EE, Forthofer MS (1998) The social consequences of psychiatric disorders, III: probability of marital stability. Am J Psychiatry 155:1092–1096. doi:10.1176/ajp.155.8.1092 PubMedCrossRef

163.

Kessler R, Foster C, Saunders W, Stang P (1995) Social consequences of psychiatric disorders, I: educational attainment. Am J Psychiatry 152:1026–1032PubMedCrossRef

164.

Pennington K, Cotter D, Dunn MJ (2005) The role of proteomics in investigating psychiatric disorders. Br J Psychiatry 187:4–6. doi:10.1192/bjp.187.1.4 PubMedCrossRef

165.

Filiou MD, Turck CW, Martins-De-Souza D (2011) Quantitative proteomics for investigating psychiatric disorders. Proteomics Clin Appl 5:38–49. doi:10.1002/prca.201000060 PubMedCrossRef

166.

Martins-de-Souza D, Guest PC, Vanattou-Saifoudine N et al (2011) The need for phosphoproteomic approaches in psychiatric research. J Psychiatr Res 45:1404–1406. doi:10.1016/j.jpsychires.2011.04.007 PubMedCrossRef

167.

Martins-de-Souza D, Guest PC, Vanattou-Saifoudine N et al (2012) Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function. Eur Arch Psychiatry Clin Neurosci 262:657–666. doi:10.1007/s00406-012-0301-3 PubMedPubMedCentralCrossRef

Title: Psychiatric disorders biochemical pathways unraveled by human brain proteomics
Authors: Verônica M. Saia-Cereda
Juliana S. Cassoli
Daniel Martins-de-Souza
Juliana M. Nascimento
Publication date: 01-02-2017
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 1/2017
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-016-0709-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Psychiatric disorders biochemical pathways unraveled by human brain proteomics

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Elevated methylation and decreased serum concentrations of BDNF in patients in levomethadone compared to diamorphine maintenance treatment

Neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy

Association between RGS4 variants and psychotic-like experiences in nonclinical individuals

Variation at NRG1 genotype related to modulation of small-world properties of the functional cortical network

Driving skills in unmedicated first- and recurrent-episode schizophrenic patients

Evidence for alterations of cortical folding in anorexia nervosa